Latest Breaking News On - Tisch cancer institute - Page 1 : vimarsana.com

ASCO 2024: Using Molecular Testing to Guide Perioperative Systemic Therapy for Urothelial Cancer

ASCO 2024 molecular testing to guide perioperative systemic therapy for urothelial cancer, ctDNA testing, adjuvant immune checkpoint blockade, TOMBOLA trial.

Frontline Nivolumab/Chemo Approved in Europe for Unresectable or Metastatic Urothelial Cancer

The European Commission approved nivolumab plus cisplatin and gemcitabine for first-line treatment in unresectable or metastatic urothelial carcinoma.

Dr Jagannath on Safety Considerations With Ide-Cel in Multiple Myeloma

Dr Jagannath on the ODAC Meeting on the Safety of Cilta-Cel in R/R Multiple Myeloma

Sundar Jagannath, MBBS, discusses takeaways from the FDA’s ODAC consensus on safety considerations with cilta-cel in relapsed/refractory multiple myeloma.

Dr Jagannath on the Safety of Linvoseltamab in Relapsed/Refractory Multiple Myeloma

Dr Jagannath on the Safety Considerations With CAR T-Cell Therapy Multiple Myeloma

Dr Jagannath on the Patient Population in the LINKER-MM1 Trial in Multiple Myeloma

Sundar Jagannath, MBBS, discusses the patient population evaluated in the LINKER-MM1 trial of linvoseltamab in relapsed/refractory multiple myeloma.

Giants of Cancer Care® Announces the 12th Annual Class of Inductees

The 15 inductees have been selected by their peers for their remarkable achievements in oncology research and clinical practice.

Decreasing Grade 3/4 Infections, Limited Hospitalizations Underscore Potential for Linvoseltamab in R/R Myeloma

Sundar Jagannath, MBBS, discusses linvoseltamab and expands on key efficacy and safety findings from the LINKER-MM1 trial in patients with relapsed/refractory multiple myeloma.

Dr Jagannath on the Potential Role for Linvoseltamab in R/R Multiple Myeloma

Sundar Jagannath, discusses the potential role for linvoseltamab in relapsed/refractory multiple myeloma.